Catabasis Pharmaceuticals to Present During the Virtual 25th International Congress of the World Muscle Society
September 23 2020 - 8:00AM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that it will present
information on the edasalonexent program, in Phase 3 development
for the treatment of Duchenne muscular dystrophy (DMD), during the
25th International Congress of the World Muscle Society which
begins September 28, 2020.
During the Virtual Poster Session on October 1, 2020 from 12:30
– 2:30pm ET, Catabasis and collaborators will present five posters
entitled:
- Inhibition of NF-kB Signaling Prevents the Development of
DMD-Associated Cardiomyopathy in mdx:Utrn+/- Mice
- Edasalonexent Maintains Bone Density and Bone Strength in the
mdx Mouse Model of Duchenne Muscular Dystrophy
- Edasalonexent Treatment in Young Boys with Duchenne Muscular
Dystrophy is Associated with Age-Normative Growth and Normal
Adrenal Function
- In the Global Phase 3 PolarisDMD Trial for Edasalonexent,
Standardized Outcome Measure Training Produces Excellent
Test-Retest Variability in the North Star Ambulatory
Assessment
- Lean Body Mass is Associated with Whole Body Mineral Density
and Muscle Strength in Treatment-Naïve, Ambulatory Boys with
Duchenne Muscular Dystrophy
The poster session will be available to registered conference
attendees during the conference and for 3 months afterwards. Select
posters will be made available in the “Our Science” section of
www.catabasis.com.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small
molecule designed to inhibit NF-kB that is being developed as a
potential foundational therapy for all patients affected by DMD,
regardless of their underlying mutation. In DMD the loss of
dystrophin leads to chronic activation of NF-kB, which is a key
driver of skeletal and cardiac muscle disease progression. The
ongoing global Phase 3 PolarisDMD trial is evaluating the efficacy
and safety of edasalonexent for registration purposes.
Edasalonexent is also being evaluated in the GalaxyDMD open-label
extension trial. In the MoveDMD Phase 2 trial and open-label
extension, the Company observed that edasalonexent preserved muscle
function and substantially slowed disease progression compared to
rates of change in a control period, and significantly improved
biomarkers of muscle health and inflammation. The FDA has granted
orphan drug, fast track, and rare pediatric disease designations
and the European Commission has granted orphan medicinal product
designation to edasalonexent for the treatment of DMD. For a
summary of clinical results, please visit www.catabasis.com.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and
life-changing therapies to patients and their families. Our lead
program is edasalonexent, an NF-kB inhibitor in Phase 3 development
for the treatment of Duchenne muscular dystrophy. For more
information on edasalonexent and our Phase 3 PolarisDMD trial,
please visit www.catabasis.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200923005114/en/
Catabasis Investor
relations: Andrea Matthews investors@catabasis.com
Media: Elizabeth Higgins media@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Sep 2023 to Sep 2024